MANA Therapeutics is harnessing the natural immune system to develop broadly accessible, ready-to-use cellular therapies to improve outcomes for cancer patients. By educating T-cells to target multiple tumor associated antigens without the need for genetic modification, MANA's EDIFY platform provides the opportunity to deliver safe, effective, and repeatable therapies.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 01/08/21 | $35,000,000 | Series A |
Cobro Ventures LifeSci Venture Partners Lightchain Capital | undisclosed |
